Lyell Immunopharma (NASDAQ:LYEL) Given New $39.00 Price Target at HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL) had its price objective reduced by HC Wainwright from $45.00 to $39.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also issued reports on LYEL. B. Riley Financial initiated coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, October 15th. Stifel Nicolaus started coverage on Lyell Immunopharma in a research note on Thursday, August 6th. They set a “buy” rating and a $36.00 price target for the company. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Lyell Immunopharma Stock Down 8.6%

NASDAQ:LYEL traded down $1.34 on Friday, reaching $14.30. 236,618 shares of the company’s stock traded hands, compared to its average volume of 231,377. The firm has a market cap of $351.64 million, a PE ratio of -1.14 and a beta of -0.04. The stock has a 50-day simple moving average of $10.99 and a 200-day simple moving average of $16.41. Lyell Immunopharma has a 12 month low of $7.20 and a 12 month high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, November 4th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($2.01) by $0.15. The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 1,701,066.75% and a negative return on equity of 107.62%. On average, equities analysts anticipate that Lyell Immunopharma will post -7.16 earnings per share for the current year.

Insider Transactions at Lyell Immunopharma

In other news, major shareholder Venture Fund Xiii L.P. Arch purchased 2,321,262 shares of the stock in a transaction on Wednesday, November 4th. The stock was bought at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the transaction, the insider owned 3,747,790 shares in the company, valued at $40,363,698.30. The trade was a 162.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Arch Venture Partners Ix, Llc bought 2,321,262 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were purchased at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the acquisition, the insider directly owned 3,747,790 shares of the company’s stock, valued at approximately $40,363,698.30. This trade represents a 162.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders sold 2,100 shares of company stock valued at $28,757. 6.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lyell Immunopharma

Large investors have recently bought and sold shares of the business. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma in the second quarter valued at $4,744,643. Opaleye Management Inc. boosted its position in shares of Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after buying an additional 264,928 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after buying an additional 76,921 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Lyell Immunopharma during the first quarter valued at $959,000. Finally, Bank of America Corp DE raised its position in Lyell Immunopharma by 314.2% during the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after buying an additional 25,276 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.